Search Results

You searched for : TreatmentforPneumococcalDisease

	U.S. FDA Accepts for Priority Review the Biologics License Application for V114 Merck announced the U.S. FDA accepted for priority review a Biologics License Application for V114, Merckâ€™s investigational 15-valent pneumococcal conjugate vaccine, for ... Jan 12
	U.S. FDA ACCEPTS FOR PRIORITY REVIEW THE BIOLOGICS LICENSE APPLICATION FOR PFIZERâ€™S INVESTIGATIONAL 20-VALENT PNEUMOCOCCAL CONJUGATE VACCINE The FDAâ€™s acceptance of our application for 20vPnC is yet another significant milestone in Pfizerâ€™s continuing efforts to help protect adults against pneumococcal ... Dec 09
	Merck Submits Applications for Licensure of V114, the Companyâ€™s Investigational 15-valent Pneumococcal Conjugate Vaccine ... Nov 23
	Merck Announces Positive Topline Results from Two Additional Phase 3 Adult Studies Evaluating V114, Merckâ€™s Investigational 15-valent Pneumococcal Conjugate Vaccine Pneumococcal disease in adults is on the rise globally, in part driven by disease-causing serotypes not targeted by the currently available pneumococcal conjugate vaccine... Oct 21
4 Matching result(s) found!

-Advertisements-

Trending Now
	Scientists in Moscow Develop Fetal Phantom for Obstetric UltrasoundNovember 19, 2024
	International Men’s Day: A Celebration of Strength, Vulnerability, and ChangeNovember 19, 2024
	The Bloody Truth: Why Menstruation Is Still a Taboo in Indian SchoolsNovember 19, 2024
	Toxic Air, Fragile Hearts: The Hidden Cost of Pollution on Heart Failure PatientsNovember 19, 2024
	Government of Telangana Hosts the AI in Healthcare Summit – Road to BioAsia 2025November 18, 2024
	In yet another groundbreaking medical milestone, Sarvodaya Hospital successfully performs India’s youngest cochlear implant on a 5- month old babyNovember 18, 2024
	Sightsavers India in collaboration with AbbVie Therapeutics India Private Limited Hosted the 4th State-Level Consultation on ‘Prevention of Visual Impairment Caused by Glaucoma’November 16, 2024
	Is Your Saree Hurting You? How Tight Waist Petticoats Could Trigger Skin CancerNovember 16, 2024
	10 New-born Lives Lost: The Jhansi Hospital Fire That Shook India’s ConscienceNovember 16, 2024
	Streax introduces revolutionary Shampoo Hair Colour in South India at accessible price point.November 15, 2024
	The Silent Killer in Your Genes: Can Splicing Errors Unlock New Cancer Cures?November 15, 2024
	Stress on a Schedule: What Your Gut Bacteria Know That You Don’tNovember 15, 2024
	A Preventable Catastrophe: Why Are Children Still Dying from Measles?November 15, 2024
	The University of Tasmania invites applications for Master of Marine and Antarctic ScienceNovember 14, 2024
	ICMR’s Bold Bet: Can India’s Scientists Deliver World-First Health Breakthroughs?November 14, 2024
	The Dark Reality Behind India’s Ayushman Bharat: Profits Before Patients?November 14, 2024
	Not a Fan of Exercise? Here’s How Few Steps You Actually Need for Better HealthNovember 14, 2024
	Shiprocket launches AI Powered Shiprocket Copilot to empower a Self-Reliant Digital Future for over 1,00,000+ Indian MSMEsNovember 13, 2024
	AIIMS Darbhanga and More: Can PM Modi’s 12,000 Crore Investment Turn Bihar into India’s Next Growth Engine?November 13, 2024
	Self-Made Survivor: How a Virologist Battled Breast Cancer with Her Own Lab-Grown VirusesNovember 13, 2024

Search Results

U.S. FDA Accepts for Priority Review the Biologics License Application for V114

U.S. FDA ACCEPTS FOR PRIORITY REVIEW THE BIOLOGICS LICENSE APPLICATION FOR PFIZERâ€™S INVESTIGATIONAL 20-VALENT PNEUMOCOCCAL CONJUGATE VACCINE

Merck Submits Applications for Licensure of V114, the Companyâ€™s Investigational 15-valent Pneumococcal Conjugate Vaccine

Merck Announces Positive Topline Results from Two Additional Phase 3 Adult Studies Evaluating V114, Merckâ€™s Investigational 15-valent Pneumococcal Conjugate Vaccine

Trending Now